Resolving the atomic level activation mechanisms of lecithin-cholesterol acyltransferase-targeted therapeutic agents utilising a novel combination of modern computational and experimental techniques
Bidragets beskrivning
Lecithin-cholesterol acyltransferase (LCAT) is one of the key enzymes in the metabolism of high-density lipoproteins (HDLs). This research project resolves the unclear activation mechanism of LCAT enzyme by utilizing therapeutic HDL-mimicking nanodiscs and small positive allosteric modulators. The study combines in a new way the state-of-the-art computational and experimental methods to achieve an atomistic description of how LCAT enzyme interacts with its activating HDL-mimetic nanodiscs and positive allosteric modulators, and how these therapeutics mechanistically activate LCAT. In addition, the mechanistic insights acquired during the project will be translated to more potent in vivo properties. The results contribute to the development of new therapeutic agents against dyslipidemic conditions. In addition, it provides a new computational and experimental platform for studying the structure and function of therapeutic nanodiscs in different contexts.
Visa merStartår
2022
Slutår
2027
Beviljade finansiering
Andra beslut
372121
Akademiforskarens forskningskostnader(2025)
200 000 €
353815
Akademiforskarens forskningskostnader(2022)
300 000 €
Finansiär
Finlands Akademi
Typ av finansiering
Akademiforskare
Utlysning
Beslutfattare
Forskningsrådet för biovetenskap, hälsa och miljö
30.05.2022
30.05.2022
Övriga uppgifter
Finansieringsbeslutets nummer
350636
Vetenskapsområden
Farmaci
Forskningsområden
Farmasia
Identifierade teman
pharmacy, biomedicine